Fig. 1

BMSC induced Gr-1^LowCD11b⁺ cells in BLM-treated mice. C57BL/6 mice were divided into three groups: sham, BLM, and BMSC. Mice in the sham group were injected intratracheally (i.t.) with 30 μL normal saline; the others were injected i.t. with 5 mg/kg BLM in 30 μL normal saline. Twenty-four hours after BLM treatment, 0.1 mL normal saline (BLM group) or BMSC suspension (1 × 10⁷/mL) (BMSC group) was injected through the tail vein. The day of intratracheal injection with BLM or saline was designated as day 0. On days 0, 3, 7, 14, 21, and 28, six mice from each group were euthanized. a The proportion of Gr-1⁺CD11b⁺ cells accumulated in the right lungs on day 7 was analyzed by flow cytometry (FCM). Representative FCM data are shown. b-c Variations of (b) Gr-1⁺CD11b⁺ cells and (c) Gr-1^HighCD11b⁺/Gr-1^LowCD11b⁺ in lungs. Data presented are representative of three replicated experiments. *P < 0.01 as compared with BMSC group; #P < 0.01 and †P < 0.05 as compared with the sham group. BLM bleomycin, BMSC bone marrow mesenchymal stem cells